Novartis lays off more in New York; DEA approves Xcelience to make Class 1 schedule drugs

> Florida-based CDMO Xcelience has been granted DEA approval to make Class I schedule drugs. Report

> Novartis ($NVS) will lay off 89 more workers starting June 30 at its Diovan plant in Suffern, NY. Report

> CDMO Recipharm has competed a serialization project in Korea for Abbott. Release

> Fusion Pharmaceuticals is recalling more than 9,400 Dicopanol kits for mixing diphenhydramine hydrochloride because of microbial contamination. Recall

> The Mississippi attorney general has asked a judge to keep the identity of the state's execution-drug supplier secret while he appeals an order to release the name. Story